Pieris Pharmaceuticals (NASDAQ: PIRS) is a clinical-stage biotechnology company whose pipeline includes locally-activated bispecifics for immuno-oncology and proprietary Anticalin proteins, a ...

BOSTON, MA / ACCESSWIRE / November 2, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) and Palvella Therapeutics, Inc. is fair ...

The merger received approval from both Palvella and Pieris stockholders, positioning the combined entity for further advancement in clinical development. Palvella Therapeutics is set to debut on ...

Roche has struck its second biotech discovery collaboration with a Boston-based biotech company in back-to-back cancer deals this week. This time the pharma giant ...

WAYNE, PA — Palvella Therapeutics, Inc. has completed its merger with Pieris Pharmaceuticals, Inc., forming a unified company under the name Palvella Therapeutics, Inc. Shares of the newly ...

"This transaction represents Pieris' deep commitment to delivering value to its stockholders by preserving the future potential milestone and royalty streams from our partnered immuno-oncology ...

Both Seattle Genetics and Pieris have been busy on the deal front lately, and today their lists grew longer as the two pair for a potential $1 billion-plus biobucks pact in immuno-oncology.